Metoprolol Tartrate Bristol Laboratories

Metoprolol tartrate, the active ingredient in Metoprolol Tartrate Bristol Laboratories, is a beta blocker presented as an oral tablet for oral use. It is indicated for hypertension, angina pectoris, post‑myocardial infarction management, heart failure and selected cardiac arrhythmias in adult patients.

GNH USA supplies Metoprolol Tartrate Bristol Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product complies with EU pharmacopeial standards and is manufactured under GMP conditions. It is distributed to a broad network of healthcare providers across Europe, Asia and the Americas.

Metoprolol tartrate is a selective β1‑adrenergic blocker used in cardiovascular conditions.

Hypertension: lowers blood pressure by reducing heart rate and cardiac output. Angina pectoris: decreases myocardial oxygen demand, relieving chest pain. Post‑myocardial infarction: improves survival and reduces risk of recurrent events. Heart failure: lowers ventricular workload and improves symptoms in chronic heart failure. Cardiac arrhythmias: controls heart rate in certain supraventricular tachyarrhythmias.

Metoprolol tartrate may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headedness, especially on standing. - Bradycardia: slower than normal heart rate. - Cold extremities: reduced blood flow to hands and feet. - Gastrointestinal upset: nausea or abdominal discomfort. - Sleep disturbances: insomnia or vivid dreams.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Heart block: impairment of electrical conduction. - Hypotension: dangerously low blood pressure. - Bronchospasm: worsening of asthma or COPD symptoms. - Heart failure exacerbation: worsening of existing heart failure. - Depression or mood changes: new or worsening depressive symptoms.

When prescribing metoprolol tartrate, clinicians should consider several precautionary measures to ensure safe use. - Dose adjustment in renal impairment: reduce dose in patients with reduced kidney function. - Caution in asthma or COPD: monitor for bronchospasm due to β‑blockade. - Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension. - Monitor heart rate and blood pressure: assess regularly during therapy. - Use with caution in diabetes: may mask hypoglycaemia symptoms. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Metoprolol tartrate can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: concurrent use may cause excessive β‑blockade. - Calcium channel blockers (verapamil, diltiazem): increase metoprolol plasma levels, risk of bradycardia. - Antidiabetic agents (insulin, sulfonylureas): may enhance hypoglycaemia risk.

Moderate Interactions (Monitor Closely): - Antihypertensives (ACE inhibitors, diuretics): additive blood pressure lowering. - Antidepressants (SSRIs, MAO inhibitors): may affect heart rate control. - NSAIDs: may reduce antihypertensive effect. - Digoxin: may increase risk of bradyarrhythmias.